News und Analysen

After a tough 2022 and gains in 2023, it's fair to say the stock market is probably on the way to better days. In any case, history tells us that bear markets, such as the one that began in 2022

After a tough 2022 and gains in 2023, it's fair to say the stock market is probably on the way to better days. In any case, history tells us that bear markets, such as the one that began in 2022

Shares of Amarin (NASDAQ: AMRN) skyrocketed 32.9% on Wednesday after the biopharmaceutical company announced strong preliminary fiscal fourth-quarter results, a new share-repurchase authorization

There are many ways one could end up with $1 million or more by retirement. Putting enough money in a savings account or winning the lottery are among them. However, neither of these methods can

There are many ways one could end up with $1 million or more by retirement. Putting enough money in a savings account or winning the lottery are among them. However, neither of these methods can

There are many ways one could end up with $1 million or more by retirement. Putting enough money in a savings account or winning the lottery are among them. However, neither of these methods can

Dividend investing is practically always in style. There is nothing quite like getting paid to own shares in a company, and for those who opt to reinvest their dividends, doing so works wonders on

Growth stocks were back in style in 2023 after a disappointing year in 2022. However, not every growth-oriented company kept pace with the broader indexes. Here are two that didn't: Sarepta

Shares of gene sequencing leader Illumina (NASDAQ: ILMN) rallied 36.6% in December, according to data from S&P Global Market Intelligence.

Investors might not be quite so excited, as Illumina

Shares of gene sequencing leader Illumina (NASDAQ: ILMN) rallied 36.6% in December, according to data from S&P Global Market Intelligence.

Investors might not be quite so excited, as Illumina

Shares of gene sequencing leader Illumina (NASDAQ: ILMN) rallied 36.6% in December, according to data from S&P Global Market Intelligence.

Investors might not be quite so excited, as Illumina

Pharmaceutical giant Pfizer (NYSE: PFE) went through a growth spurt during the COVID-19 pandemic as one of the leading vaccine companies. But the windfall of billions of extra dollars in revenue and

Pharmaceutical giant Pfizer (NYSE: PFE) went through a growth spurt during the COVID-19 pandemic as one of the leading vaccine companies. But the windfall of billions of extra dollars in revenue and

If you're a dividend investor with a leaning toward value investing, you'll want to do a deep dive on Medtronic (NYSE: MDT), Texas Instruments (NASDAQ: TXN), and, perhaps, even Stanley Black &amp

Pfizer (NYSE: PFE) had a disastrous 2023, with its share price collapsing by 44%. It was one of the S&P 500's worst-performing stocks last year. The company's COVID-19 revenue nosedived as the

Pfizer (NYSE: PFE) had a disastrous 2023, with its share price collapsing by 44%. It was one of the S&P 500's worst-performing stocks last year. The company's COVID-19 revenue nosedived as the

It isn't unusual for top medical device maker Medtronic (NYSE: MDT) to score regulatory approvals for its goods. Nevertheless, in the healthcare field, nearly any regulatory win is considered a

Investing in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but breaking new ground can sometimes offer outsized rewards. On that note, Editas Medicine (NASDAQ:

Pharmaceutical company AbbVie (NYSE: ABBV) has been a double-deal of price growth and dividend income over the past five years. It achieved 129% in total returns in that time, outpacing the S&P 500.